Even with the slightest glance at the presentations and discussions being held at the American Society For Preventive Cardiology (ASPC) virtual summit in 2021, it is clear that a lot is happening in the field of cardiovascular disease prevention.
One of the most advanced presentations, Technologies and Wearables, came from Seth Martin, MD, who leads The Mobile Technologies to Achieve Equity in Cardiovascular Health at Johns Hopkins Medicine.
Martin spoke in an interview with HCPLive about the ongoing COVID-19 pandemic and its impact on cardiology research as well as the future of cardiovascular technologies.
“In a way, I mean (COVID-19) has shed some light on the fact that there is different access,” Martin said. “But in a way it speeds the future of access because we got a taste of what it is like to really need technology for care. I think it has accelerated our overall path to that, the future of care to which we have much better access. “
Acceleration, which Martin alluded to in previous reports, is as important a concern as accessibility. He has challenged fellow cardiology researchers to develop new strategies and technologies that are easily accessible to their patients.
One project Martin has worked closely on over the past 5 years at Johns Hopkins Medicine is the Corrie Health App. In collaboration with Dr. Francoise Marvel and senior engineer Matthias Lee, as well as members of the Apple Health Team, he was involved in the development of smartphone technology with a strong focus on preventive cardiology.
Martin and colleagues recently published encouraging results on circulatory quality and the results of 200 patients who had a heart attack and participated in a health intervention through the Corrie Health app.
One point Martin was proud of was that much of what was built into the application was based on patient input coupled with the latest cardiac guidelines.
Martin spoke of the importance of high quality care for patients with cardiovascular diseases and the importance of strengthening patient confidence.
“They will then have that self-confidence,” said Martin. “Ultimately, the (trust) that you are guided by a program and know what to do will decide or break patient outcomes. That will decide whether you take your antiplatelet drugs or your cholesterol-lowering therapy. “